Clinical trials: Trop2
Breast Cancer
NIR Fluorescent Molecular Probe for the Identification of Breast Tissue
Accurate evaluation of tumor boundaries in breast-conserving surgery is critical to reducing the second operation of patients. Near-infrared (NIR) fluorescence imaging using molecular agents has shown promise for in situ imaging…
- Trial name
- NIR (NCT05708144)
- Testing
- ICG-SG incubation solution
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Xiang'an Hospital of Xiamen University
Breast Cancer
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with…
- Trial name
- NCT06112379
- Testing
- Dato-DXd, Durvalumab, Pembrolizumab
- Where
- 283 sites in United States, Australia and 24 more
- Volunteers
- 1,902 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation…
- Trial name
- NCT05609968
- Testing
- Sacituzumab Govitecan, Pembrolizumab
- Where
- 180 sites in United States, Australia and 23 more
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
This study aims to evaluate the efficacy and safety of DS-1062a in participants with metastatic, unresectable NSCLC having progressed on one, but not more than three previous standard therapies.
- Conditions
- Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer
- Trial name
- ICARUS-LUNG01 (NCT04940325)
- Testing
- DS-1062a
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy.
- Trial name
- TroFuse-005 (NCT06132958)
- Testing
- Sacituzumab tirumotecan, Doxorubicin, Paclitaxel
- Where
- 242 sites in United States, Argentina and 29 more
- Volunteers
- 710 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab…
- Trial name
- BALISTA (NCT06793332)
- Testing
- Ivonescimab Combined With TROP2 ADC
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fudan University
Advanced or Metastatic Breast Cancer
The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
The incidence of oral mucositis associated with TROP2-ADC therapy in patients with advanced breast cancer is notably high. Identifying effective preventive and therapeutic strategies is essential for enhancing patient quality of…
- Trial name
- NCT06934733
- Testing
- Oral cryotherapy, Routine oral care
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Henan Cancer Hospital
Advanced Hepatocellular Carcinoma (HCC)
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
This study is a prospective, single-arm, open, single-center clinical trial initiated by the investigator. The principal investigators are professors Shen Feng and Zhang Xiaofeng from The Third Affiliated Hospital of Navy…
- Trial name
- NCT06902389
- Testing
- Super Hi-TCR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Ovarian Carcinoma
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
- Trial name
- NCT06028932
- Testing
- Sacituzumab govitecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University